<DOC>
	<DOCNO>NCT00000730</DOCNO>
	<brief_summary>This study compare three different therapy treatment refractory Pneumocystis carinii pneumonia ( PCP ) patient AIDS . `` Refractory '' mean patient fail respond least 4 day treatment either two standard therapy : ( 1 ) sulfamethoxazole/trimethoprim ( SMX/TMP ) ( 2 ) pentamidine ( PEN ) . This study compare therapy trimetrexate ( TMTX ) leucovorin ( LCV ) standard therapy standard therapy plus high-dose steroid ( methylprednisolone ) . The purpose find well safer form treatment PCP AIDS patient . There present scientific information best treatment AIDS patient PCP improve receive standard therapy ( SMX/TMP PEN ) . New drug treatment available , include steroid therapy TMTX , information prove new treatment work well standard therapy .</brief_summary>
	<brief_title>Comparison Three Treatments Pneumocystis Pneumonia AIDS Patients</brief_title>
	<detailed_description>There present scientific information best treatment AIDS patient PCP improve receive standard therapy ( SMX/TMP PEN ) . New drug treatment available , include steroid therapy TMTX , information prove new treatment work well standard therapy . Hospitalized patient fail respond least 4 full day great 14 full day therapy SMX/TMP PEN randomly place one three study group . Patients stratify ( 1 ) mechanical ventilation enrollment , ( 2 ) prior zidovudine therapy least 4 week duration , ( 3 ) first versus subsequent episode PCP . One group patient receive TMTX intravenous infusion 21 day LCV 24 day . The second third group patient receive either PEN SMX/TMP depend therapy already receive improved . The difference second third group second group receive conventional therapy ( PEN SMX/TMP ) placebo ( inactive medication ) third group receive conventional therapy prednisolone . Neither investigators patient know whether patient receive methylprednisolone . Patients continue study treatment study end point reach minimum 21 day ( unless toxicity ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : physiologic replacement dos steroid . Pneumocystis carinii pneumonia ( PCP ) patient HIV positive ELISA , HIV culture , p24 antigenemia , member risk group HIV infection . Failed least 4 &gt; 14 full day ' therapy either sulfamethoxazole/trimethoprim ( SMX/TMP ) parenteral pentamidine . Patients must receive therapy one two conventional agent prior enrollment . Patients unequivocal diagnosis episode PCP establish morphologic confirmation three typical Pneumocystis carinii organism sputum , bronchoalveolar lavage fluid , lung tissue obtain transbronchial open lung biopsy within 15 day prior study entry . Patients significant improvement arterialalveolar oxygen pressure ( defined decrease least 15mm Hg ) observe 24 hour prior entry . Patient willing maximal medical support , include pressor , invasive monitoring , and/or mechanical ventilation , least first 7 day protocol therapy support necessary . Continuation maximal medical support beyond 7 day discretion investigator patient . Patients history hypersensitivity less severe type I may enrol , opinion investigator , adverse effect prohibit rechallenge drug . Prior Medication : Required : At least 4 full day great 14 full day parenteral and/or oral therapy sulfamethoxazole/trimethoprim ( SMX/TMP ) pentamidine . Allowed : Zidovudine ( AZT ) . Exclusion Criteria Coexisting Condition : Excluded : Patients history type I hypersensitivity ( urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction secondary trimetrexate , sulfamethoxazole/trimethoprim , pentamidine . Presence process , opinion investigator , would adversely seriously affected steroid therapy . Failure meet inclusion criterion . Concurrent Medication : Excluded : Zidovudine ( AZT ) . Myelosuppressive agent . Nephrotoxic agent . AZT may resume completion study . Excluded : Patients history type I hypersensitivity ( urticaria , angioedema , anaphylaxis ) , exfoliative dermatitis , lifethreatening reaction secondary trimetrexate , sulfamethoxazole/trimethoprim , pentamidine . Presence process , opinion investigator , would adversely seriously affected steroid therapy . Failure meet inclusion criterion . Prior Medication : Excluded within 4 day study entry : Any investigational agent . Excluded within 14 day study entry : Steroids ( physiologic replacement dos ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Trimetrexate</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Folic Acid Antagonists</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>